Group 1 - A class action lawsuit has been filed on behalf of investors who purchased securities of Savara Inc. (NASDAQ: SVRA) during the specified class period from March 7, 2024, to May 23, 2025 [1] - Savara Inc. is identified as a clinical-stage biopharmaceutical company [1] - The lawsuit is being investigated by Rosen Law Firm, which specializes in investor rights [1]

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1] Group 1: Allegations and Impact - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2] - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2] - As a result, the public statements made by Savara were materially false and misleading during the relevant period [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request to be appointed as lead plaintiff in the case [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - Savara Inc. is facing a securities fraud class action lawsuit following a significant decline in its stock price after the FDA issued a refusal to file letter for its MOLBREEVI BLA therapy [3][4]. Group 1: Company Overview - Savara Inc. (NASDAQ:SVRA) is involved in the development of therapies, specifically the MOLBREEVI BLA intended for treating patients with aPap [3]. - The company experienced a stock price drop of approximately 31.69%, from $2.84 on May 23, 2025, to $1.94 on May 27, 2025, after the FDA's announcement [3]. Group 2: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Savara securities between March 7, 2024, and May 23, 2025 [4]. - Allegations in the lawsuit include that Savara made false or misleading statements regarding the completeness of the MOLBREEVI BLA submission and the likelihood of FDA approval [4]. - The lawsuit claims that the company failed to disclose the need for additional data related to Chemistry, Manufacturing, and Controls (CMC), which impacted the approval timeline and raised concerns about the need for additional capital [4].

Group 1 - The article highlights the upcoming deadline of November 7, 2025, for investors to file a lead plaintiff motion in a case concerning Savara Inc. (NASDAQ: SVRA) [1] - The case is on behalf of investors who purchased Savara securities during the class period from March 7, 2024, to May 23, 2025 [1] - Investors who suffered losses in Savara Inc. are encouraged to contact the Law Offices of Howard G. Smith to participate in the ongoing securities litigation [1]

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - The public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial obligation to participate [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - Savara Inc. (NASDAQ: SVRA) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its drug MOLBREEVI, which is intended for the treatment of pulmonary alveolar proteinosis [3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from March 4, 2024, to May 23, 2025 [3]. - Allegations include that Savara failed to disclose critical information about MOLBREEVI's chemistry, manufacturing, and controls, leading to doubts about FDA approval [3]. - The complaint suggests that the delay in regulatory approval could necessitate Savara to raise additional capital [3]. Group 2: Shareholder Actions - Shareholders who purchased SVRA shares during the class period are encouraged to register for the class action and may seek lead plaintiff status [1][4]. - The deadline for shareholders to register is November 7, 2025, and there is no cost to participate [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Group 3: Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class Action. ...

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during the specified class period [1][2]. Group 1: Allegations and Company Performance - The complaint alleges that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), specifically that it lacked sufficient details on chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - Following the announcement of a refusal to file (RTF) letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [3]. Group 2: Legal Proceedings and Participation - Shareholders may be eligible to participate in the class action against Savara Inc., with the option to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Core Viewpoint - Savara, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its lead product candidate, MOLBREEVI, and its Biologics License Application (BLA) submission to the FDA [1][4]. Company Overview - Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases [3]. - The company's lead product candidate is MOLBREEVI (molgramostim), an inhaled granulocyte-macrophage colony-stimulating factor [3]. - In December 2024, Savara began a rolling submission of a BLA to the FDA for MOLBREEVI to treat aPAP [3]. Legal Issues - The class action lawsuit alleges that Savara made false or misleading statements and failed to disclose critical information about the MOLBREEVI BLA, including insufficient data on chemistry, manufacturing, and controls [4]. - The lawsuit claims that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay the submission timeline and necessitate additional capital raising [4]. - On May 27, 2025, Savara announced it received a refusal to file (RTF) letter from the FDA, stating the BLA was not sufficiently complete for review, leading to a more than 31% drop in share price [5].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Savara Inc. ("Savara†or the "Company†) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the "Class Period†). Savara investors have until November 7, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE. ...